Mor­phoSys CFO Sung Lee ex­its as shares suf­fer in mar­ket melt­down

Just ahead of what would have been his sec­ond an­niver­sary as chief fi­nan­cial of­fi­cer at Mor­phoSys, Sung Lee put out word that he is ex­it­ing the Ger­man biotech and head­ed back to the US.

The biotech says that Lee will be re­turn­ing to Cal­i­for­nia — for per­son­al rea­sons.

Lee’s tenure at Mor­phoSys has been event­ful. He’s been giv­en cred­it for play­ing a ma­jor role in the Con­stel­la­tion buy­out just months af­ter his ar­rival, which de­liv­ered pelabre­sib (CPI-0610), billed at the time as a po­ten­tial first and best-in-class BET in­hibitor, and CPI-0209, a sec­ond-gen­er­a­tion EZH2 in­hibitor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER